163 related articles for article (PubMed ID: 24875132)
1. Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.
Kurata T; Tsurutani J; Fujisaka Y; Okamoto W; Hayashi H; Kawakami H; Shin E; Hayashi N; Nakagawa K
Invest New Drugs; 2014 Oct; 32(5):946-54. PubMed ID: 24875132
[TBL] [Abstract][Full Text] [Related]
2. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.
Tjulandin S; Moiseyenko V; Semiglazov V; Manikhas G; Learoyd M; Saunders A; Stuart M; Keilholz U
Invest New Drugs; 2014 Feb; 32(1):145-53. PubMed ID: 23589215
[TBL] [Abstract][Full Text] [Related]
3. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
Thomas A; Virdee PS; Eatock M; Lord SR; Falk S; Anthoney DA; Turkington RC; Goff M; Elhussein L; Collins L; Love S; Moschandreas J; Middleton MR
Eur J Cancer; 2020 Jan; 124():131-141. PubMed ID: 31765988
[TBL] [Abstract][Full Text] [Related]
4. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Johnston S; Basik M; Hegg R; Lausoontornsiri W; Grzeda L; Clemons M; Dreosti L; Mann H; Stuart M; Cristofanilli M
Breast Cancer Res Treat; 2016 Nov; 160(1):91-99. PubMed ID: 27654971
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer.
Inoue K; Kuroi K; Shimizu S; Rai Y; Aogi K; Masuda N; Nakayama T; Iwata H; Nishimura Y; Armour A; Sasaki Y
Int J Clin Oncol; 2015 Dec; 20(6):1102-9. PubMed ID: 25967286
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Schneeweiss A; Park-Simon TW; Albanell J; Lassen U; Cortés J; Dieras V; May M; Schindler C; Marmé F; Cejalvo JM; Martinez-Garcia M; Gonzalez I; Lopez-Martin J; Welt A; Levy C; Joly F; Michielin F; Jacob W; Adessi C; Moisan A; Meneses-Lorente G; Racek T; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
Invest New Drugs; 2018 Oct; 36(5):848-859. PubMed ID: 29349598
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
Zhang J; Cao J; Li J; Zhang Y; Chen Z; Peng W; Sun S; Zhao N; Wang J; Zhong D; Zhang X; Zhang J
J Hematol Oncol; 2014 Mar; 7():22. PubMed ID: 24612546
[TBL] [Abstract][Full Text] [Related]
11. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
12. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Propper DJ; Gao F; Saunders MP; Sarker D; Hartley JA; Spanswick VJ; Lowe HL; Hackett LD; Ng TT; Barber PR; Weitsman GE; Pearce S; White L; Lopes A; Forsyth S; Hochhauser D
Br J Cancer; 2023 Jan; 128(2):245-254. PubMed ID: 36352028
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer.
Seto T; Hirai F; Saka H; Kogure Y; Yoh K; Niho S; Fukase K; Shimada H; Sasai M; Fukino K
Jpn J Clin Oncol; 2018 Jan; 48(1):31-42. PubMed ID: 29136201
[TBL] [Abstract][Full Text] [Related]
15. Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.
Ballard P; Swaisland HC; Malone MD; Sarda S; Ghiorghiu S; Wilbraham D
Xenobiotica; 2014 Dec; 44(12):1083-98. PubMed ID: 25007130
[TBL] [Abstract][Full Text] [Related]
16. Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Patnaik A; Wood D; Tolcher AW; Hamilton M; Kreisberg JI; Hammond LA; Schwartz G; Beeram M; Hidalgo M; Mita MM; Wolf J; Nadler P; Rowinsky EK
Clin Cancer Res; 2006 Dec; 12(24):7406-13. PubMed ID: 17189413
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
Milojkovic Kerklaan B; Diéras V; Le Tourneau C; Mergui-Roelvink M; Huitema AD; Rosing H; Beijnen JH; Marreaud S; Govaerts AS; Piccart-Gebhart MJ; Schellens JH; Awada A
Cancer Chemother Pharmacol; 2013 Jan; 71(1):53-62. PubMed ID: 23053259
[TBL] [Abstract][Full Text] [Related]
19. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.
Hickish T; Mehta A; Liu MC; Huang CS; Arora RS; Chang YC; Yang Y; Vladimirov V; Jain M; Tsang J; Pemberton K; Sadrolhefazi B; Jin X; Tseng LM
Breast Cancer Res Treat; 2022 Apr; 192(3):593-602. PubMed ID: 35138529
[TBL] [Abstract][Full Text] [Related]
20. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Vermorken JB; Rottey S; Ehrnrooth E; Pelling K; Lahogue A; Wind S; Machiels JP
Ann Oncol; 2013 May; 24(5):1392-400. PubMed ID: 23293114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
